Thomson David 4
4 · MANNKIND CORP · Filed Mar 25, 2026
Research Summary
AI-generated summary of this filing
MannKind EVP David Thomson Receives RSU Awards (MNKD)
What Happened David Thomson, EVP General Counsel & Secretary of MannKind Corp (MNKD), received two restricted stock unit (RSU) awards on March 23, 2026 totaling 438,000 RSUs (221,000 and 217,000). Each award was granted at $0.00 (no cash paid) and reported as derivative awards. These are grants of future stock contingent on vesting conditions rather than open-market purchases or sales.
Key Details
- Transaction date: March 23, 2026; Form 4 filed March 25, 2026 (timely).
- Grants: 221,000 RSUs and 217,000 RSUs (total 438,000 RSUs) at $0.00 per unit (derivative awards).
- Shares owned after transaction: not specified in the filing.
- Footnotes of note:
- F1: Each RSU represents a contingent right to receive one share of MNKD common stock upon vesting.
- F2: The performance-based RSU vests Jan 15, 2029; payout 0%–300% of target based on MannKind TSR vs. Russell 3000 Pharma & Biotech over Apr 1, 2026–Dec 31, 2028 (interpolated).
- F3: The time-based RSU vests 25% on March 23, 2027, then 1/16th quarterly thereafter.
- Transaction code: A = Award/Grant.
Context RSU grants are a form of compensation and do not involve an immediate cash purchase or sale of shares. One award is time-based (standard vesting schedule); the other is performance-based with a potential multiplier depending on total shareholder return versus a benchmark index. Because these are awards, they reflect compensation decisions rather than direct insider buying/selling activity.
Insider Transaction Report
- Award
Performance Restricted Stock Unit
[F1][F2]2026-03-23+221,000→ 221,000 total→ Common Stock, $0.01 Par Value (221,000 underlying) - Award
Employee Stock Option (right to buy)
[F3]2026-03-23+217,000→ 217,000 totalExercise: $2.44From: 2027-03-23Exp: 2036-03-23→ Common Stock, $0.01 Par Value (217,000 underlying)
Footnotes (3)
- [F1]Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
- [F2]The performance-based restricted stock unit will vest on January 15, 2029. The number of shares delivered on the vesting date, as a percentage of the target specified [in Box 5 above], is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from April 1, 2026 until December 31, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the measurement period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.
- [F3]25% vesting on March 23, 2027 and thereafter 1/16th quarterly.